Diabetes Care, Vol 22, Issue 1 119-124, Copyright © 1999 by American Diabetes Association

ARTICLES

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes

R Moses, R Slobodniuk, S Boyages, S Colagiuri, W Kidson, J Carter, T Donnelly, P Moffitt and H Hopkins
Department of Endocrinology, Illawarra Regional Hospital, Wollongong, Australia. robert_moses@uow.edu.au

OBJECTIVE: To compare the effect of repaglinide in combination with metformin with monotherapy of each drug on glycemic control in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 83 patients with type 2 diabetes who had inadequate glycemic control (HbA1c > 7.1%) when receiving the antidiabetic agent metformin were enrolled in this multicenter, double-blind trial. Subjects were randomized to continue with their prestudy dose of metformin (n = 27), to continue with their prestudy dose of metformin with the addition of repaglinide (n = 27), or to receive repaglinide alone (n = 29). For patients receiving repaglinide, the optimal dose was determined during a 4- to 8-week titration and continued for a 3-month maintenance period. RESULTS: In subjects receiving combined therapy, HbA1c was reduced by 1.4 +/- 0.2%, from 8.3 to 6.9% (P = 0.0016) and fasting plasma glucose by 2.2 mmol/l (P = 0.0003). No significant changes were observed in subjects treated with either repaglinide or metformin monotherapy in HbA1c (0.4 and 0.3% decrease, respectively) or fasting plasma glucose (0.5 mmol/l increase and 0.3 mmol/l decrease respectively). Subjects receiving repaglinide either alone or in combination with metformin, had an increase in fasting levels of insulin between baseline and the end of the trial of 4.04 +/- 1.56 and 4.23 +/- 1.50 mU/l, respectively (P < 0.02). Gastrointestinal adverse events were common in the metformin group. An increase in body weight occurred in the repaglinide and combined therapy groups (2.4 +/- 0.5 and 3.0 +/- 0.5 kg, respectively; P < 0.05). CONCLUSIONS: Combined metformin and repaglinide therapy resulted in superior glycemic control compared with repaglinide or metformin monotherapy in patients with type 2 diabetes whose glycemia had not been well controlled on metformin alone. Repaglinide monotherapy was as effective as metformin monotherapy.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. Bachmakov, H. Glaeser, M. F. Fromm, and J. Konig Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters: Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1 Diabetes, June 1, 2008; 57(6): 1463 - 1469. [Abstract] [Full Text] [PDF]

				M. J. Abrahamson A 74-Year-Old Woman With Diabetes JAMA, January 10, 2007; 297(2): 196 - 204. [Abstract] [Full Text] [PDF]

				B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]

				M. J. Abrahamson Optimal Glycemic Control in Type 2 Diabetes Mellitus: Fasting and Postprandial Glucose in Context Arch Intern Med, March 8, 2004; 164(5): 486 - 491. [Abstract] [Full Text] [PDF]

				R. R. Koski Oral Antidiabetic Agents: A Comparative Review Journal of Pharmacy Practice, February 1, 2004; 17(1): 39 - 48. [Abstract] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				A. J. Garber, D. S. Donovan Jr., P. Dandona, S. Bruce, and J.-S. Park Efficacy of Glyburide/Metformin Tablets Compared with Initial Monotherapy in Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3598 - 3604. [Abstract] [Full Text] [PDF]

				{blacktriangledown}Nateglinide and {blacktriangledown}repaglinide for type 2 diabetes? DTB, July 1, 2003; 41(7): 52 - 54. [Abstract] [Full Text] [PDF]

				P. Raskin, L. Klaff, J. McGill, S. A. South, P. Hollander, N. Khutoryansky, and P. M. Hale Efficacy and Safety of Combination Therapy: Repaglinide plus metformin versus nateglinide plus metformin Diabetes Care, July 1, 2003; 26(7): 2063 - 2068. [Abstract] [Full Text] [PDF]

				J. L. Chan and M. J. Abrahamson Pharmacological Management of Type 2 Diabetes Mellitus: Rationale for Rational Use of Insulin Mayo Clin. Proc., April 1, 2003; 78(4): 459 - 467. [Abstract] [PDF]

				P. Phillips, J. Karrasch, R. Scott, D. Wilson, and R. Moses Acarbose Improves Glycemic Control in Overweight Type 2 Diabetic Patients Insufficiently Treated With Metformin Diabetes Care, February 1, 2003; 26(2): 269 - 273. [Abstract] [Full Text] [PDF]

				N. J. Furlong, S. A. Hulme, S. V. O'Brien, and K. J. Hardy Repaglinide Versus Metformin in Combination With Bedtime NPH Insulin in Patients With Type 2 Diabetes Established on Insulin/Metformin Combination Therapy Diabetes Care, October 1, 2002; 25(10): 1685 - 1690. [Abstract] [Full Text] [PDF]

				C. A Reasner and B. Goke Overcoming the barriers to effective glycaemic control for type 2 diabetes The British Journal of Diabetes & Vascular Disease, July 1, 2002; 2(4): 290 - 295. [PDF]

				S. E. Inzucchi Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review JAMA, January 16, 2002; 287(3): 360 - 372. [Abstract] [Full Text] [PDF]

				M. Saleh and G. Grunberger Hypoglycemia: An Excuse for Poor Glycemic Control? Clin. Diabetes, October 1, 2001; 19(4): 161 - 167. [Abstract] [Full Text] [PDF]

				D. A. de Luis, R. Aller, L. Cuellar, C. Terroba, H. Ovalle, O. Izaola, and E. Romero Effect of Repaglinide Addition to NPH Insulin Monotherapy on Glycemic Control in Patients With Type 2 Diabetes Diabetes Care, October 1, 2001; 24(10): 1844 - 1845. [Full Text] [PDF]

				R. G. Moses, R. Gomis, K. B. Frandsen, J.-L. Schlienger, and I. Dedov Flexible Meal-Related Dosing With Repaglinide Facilitates Glycemic Control in Therapy-Naive Type 2 Diabetes Diabetes Care, January 1, 2001; 24(1): 11 - 15. [Abstract] [Full Text]

				S. Campbell Management of Type 2 Diabetes in the Geriatric Patient Journal of Pharmacy Practice, August 1, 2000; 13(4): 263 - 276. [Abstract] [PDF]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]